FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:1607-1611 December 15, 1994 Number 24 Next

	Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background In Scandinavia many patients with primary hypogammaglobulinemia contracted non-A, non-B hepatitis after intravenous treatment with an immune globulin product that was later found to contain a non-A, non-B hepatitis virus.

Methods We studied the prevalence and clinical course of hepatitis C virus (HCV) infection in a group of 55 Norwegian patients with primary hypogammaglobulinemia and investigated its association with the use of contaminated immune globulin. We used the polymerase chain reaction to detect HCV RNA and performed HCV genotyping. We also analyzed the responses to treatment with interferon.

Results Of 20 patients who received the contaminated immune globulin, 17 were seropositive for HCV RNA. In addition, 1 of 35 patients not exposed to the contaminated immune globulin was HCV RNA-positive. HCV genotype V was found in all 12 patients for whom genotyping was performed, but 8 patients also had genotype II or III, or both. All HCV RNA-positive patients had abnormal results on biochemical liver tests. All liver-biopsy specimens (from 15 patients) were abnormal, with portal inflammation, bile-duct damage, and focal necrosis. In six patients there was cirrhosis. Two patients died of liver failure. In 4 of the 10 patients treated with interferon there were complete, though transient, biochemical responses, but the follow-up biopsy specimens showed evidence of histologic progression. The poorest responses to interferon were among the patients with multiple HCV genotypes. All but one patient remained positive for HCV RNA.

Conclusions In patients with primary hypogammaglobulinemia there was a high rate of HCV infection after treatment with contaminated immune globulin. In these immunocompromised patients HCV infection has a severe and rapidly progressive course, and responses to interferon are poor.

Source Information

From the Section of Clinical Immunology and Infectious Diseases (K.B., S.S.F.) and the Section of Hepatology and Gastroenterology (K.B.), Medical Department A, and the Department of Pathology (T.H.), National Hospital, Oslo, Norway; the Department of Virology, National Institute of Public Health, Oslo (H.H.S.); and the Institute for Clinical Virology, Karolinska Institute, Huddinge Hospital, Stockholm, Sweden (Z.Y.).

Address reprint requests to Dr. Bjoro at Medical Department A, National Hospital, 0027 Oslo, Norway.

Full Text of this Article

Related Letters:

Hepatitis C and Immune Globulin
Douglas S. D., Slade H. B., López-Jiménez J., Odriozola J., Pérez-Oteyza J., García-Laraña J., Prince A. M., Horowitz B., Bjøro K., Frøland S. S., Schiff R. I.
Extract | Full Text  
N Engl J Med 1995; 332:1235-1237, May 4, 1995. Correspondence

This article has been cited by other articles:

• Lavillette, D., Morice, Y., Germanidis, G., Donot, P., Soulier, A., Pagkalos, E., Sakellariou, G., Intrator, L., Bartosch, B., Pawlotsky, J.-M., Cosset, F.-L. (2005). Human Serum Facilitates Hepatitis C Virus Infection, and Neutralizing Responses Inversely Correlate with Viral Replication Kinetics at the Acute Phase of Hepatitis C Virus Infection. J. Virol. 79: 6023-6034 [Abstract] [Full Text]  
• Sundstrom, S., Ota, S., Dimberg, L. Y., Masucci, M. G., Bergqvist, A. (2005). Hepatitis C Virus Core Protein Induces an Anergic State Characterized by Decreased Interleukin-2 Production and Perturbation of Mitogen-Activated Protein Kinase Responses. J. Virol. 79: 2230-2239 [Abstract] [Full Text]  
• Brannagan, T. H. III (2002). Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies. Neurology 59: S33-40 [Abstract] [Full Text]  
• Angelucci, E., Muretto, P., Nicolucci, A., Baronciani, D., Erer, B., Gaziev, J., Ripalti, M., Sodani, P., Tomassoni, S., Visani, G., Lucarelli, G. (2002). Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 100: 17-21 [Abstract] [Full Text]  
• Bugli, F., Mancini, N., Kang, C.-Y., Di Campli, C., Grieco, A., Manzin, A., Gabrielli, A., Gasbarrini, A., Fadda, G., Varaldo, P. E., Clementi, M., Burioni, R. (2001). Mapping B-Cell Epitopes of Hepatitis C Virus E2 Glycoprotein Using Human Monoclonal Antibodies from Phage Display Libraries. J. Virol. 75: 9986-9990 [Abstract] [Full Text]  
• Espinosa, M., Martin-Malo, A., de Lara, M. A. A., Aljama, P. (2001). Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant 16: 1669-1674 [Abstract] [Full Text]  
• Booth, J C L, O'Grady, J, Neuberger, J (2001). Clinical guidelines on the management of hepatitis C. Gut 49: I1-21 [Full Text]  
• Tillmann, H L, Chen, D-F, Trautwein, C, Kliem, V, Grundey, A, Berning-Haag, A, Boker, K, Kubicka, S, Pastucha, L, Stangel, W, Manns, M P (2001). Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease. Gut 48: 714-718 [Abstract] [Full Text]  
• Allander, T., Drakenberg, K., Beyene, A., Rosa, D., Abrignani, S., Houghton, M., Widell, A., Grillner, L., Persson, M. A. A. (2000). Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J. Gen. Virol. 81: 2451-2459 [Abstract] [Full Text]  
• Sia, I. G., Patel, R. (2000). New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant Recipients. Clin. Microbiol. Rev. 13: 83-121 [Abstract] [Full Text]  
• BIZOLLON, T, TREPO, C (1999). Transplantation in HCV: whither immunosuppression. Gut 45: 327-328 [Full Text]  
• BjOro, K., Skaug, K., Haaland, T., FrOland, S.S. (1999). Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia. QJM 92: 433-441 [Abstract] [Full Text]  
• Paul, I. M., Sanders, J., Ruggiero, F., Andrews, T., Ungar, D., Eyster, M. E. (1999). Chronic Hepatitis C Virus Infections in Leukemia Survivors: Prevalence, Viral Load, and Severity of Liver Disease. Blood 93: 3672-3677 [Abstract] [Full Text]  
• Strasser, S. I., Sullivan, K. M., Myerson, D., Spurgeon, C. L., Storer, B., Schoch, H. G., Murakami, C. S., McDonald, G. B. (1999). Cirrhosis of the Liver in Long-Term Marrow Transplant Survivors. Blood 93: 3259-3266 [Abstract] [Full Text]  
• Kenny-Walsh, E., The Irish Hepatology Research Group, (1999). Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune Globulin. NEJM 340: 1228-1233 [Abstract] [Full Text]  
• Strasser, S. I., McDonald, G. B. (1999). Hepatitis Viruses and Hematopoietic Cell Transplantation: A Guide to Patient and Donor Management. Blood 93: 1127-1136 [Full Text]  
• Yamada-Osaki, M., Sumazaki, R., Tsuchida, M., Koike, K., Fukushima, T., Matsui, A. (1999). Persistence and Clinical Outcome of Hepatitis G Virus Infection in Pediatric Bone Marrow Transplant Recipients and Children Treated for Hematological Malignancy. Blood 93: 721-727 [Abstract] [Full Text]  
• Schneeberger, P. M., Keur, I., van der Vliet, W., van Hoek, K., Boswijk, H., van Loon, A. M., van Dijk, W. C., Kauffmann, R. H., Quint, W., van Doorn, L.-J. (1998). Hepatitis C Virus Infections in Dialysis Centers in The Netherlands: a National Survey by Serological and Molecular Methods. J. Clin. Microbiol. 36: 1711-1715 [Abstract] [Full Text]  
• Calpin, C., Dick, P., Poon, A., Feldman, W. (1998). Is Bone Marrow Aspiration Needed in Acute Childhood Idiopathic Thrombocytopenic Purpura to Rule Out Leukemia?. Arch Pediatr Adolesc Med 152: 345-347 [Abstract] [Full Text]  
• Committee on Infectious Diseases, (1998). Hepatitis C Virus Infection. Pediatrics 101: 481-485 [Abstract] [Full Text]  
• Rossi, G., Tucci, A., Cariani, E., Ravaggi, A., Rossini, A., Radaeli, E. (1997). Outbreak of Hepatitis C Virus Infection in Patients With Hematologic Disorders Treated With Intravenous Immunoglobulins: Different Prognosis According to the Immune Status. Blood 90: 1309-1314 [Abstract] [Full Text]  
• Pol, S., Garrigue, V., Legendre, C., Heneghan, M. A., Gane, E. J., Naoumov, N. V., Williams, R. (1996). Long-Term Outcome of Hepatitis C Infection after Liver Transplantation. NEJM 335: 522-523 [Full Text]  
• Ryan, M. E., Webster, M. L., Statler, J. D. (1996). Averse Effects of Intravenous Immunoglobulin Therapy. CLIN PEDIATR 35: 23-31  
• Rosen, F. S., Cooper, M. D., Wedgwood, R. J.P. (1995). The Primary Immunodeficiencies. NEJM 333: 431-440 [Full Text]  
• Douglas, S. D., Slade, H. B., Lopez-Jimenez, J., Odriozola, J., Perez-Oteyza, J., Garcia-Larana, J., Prince, A. M., Horowitz, B., Bjoro, K., Froland, S. S., Schiff, R. I. (1995). Hepatitis C and Immune Globulin. NEJM 332: 1235-1237 [Full Text]  
• Mofenson, L. M., Nugent, R., Spector, S. A., Gelber, R. D., Wara, D. W. (1995). Prophylactic Immune Globulin in Children with HIV Disease. NEJM 332: 750-752 [Full Text]  
• Schiff, R. I. (1994). Transmission of Viral Infections through Intravenous Immune Globulin. NEJM 331: 1649-1650 [Full Text]